ライフサイエンスコーパス: laboratory data

1 show credible results when compared against laboratory data.

2 OVID-19 requires integration of clinical and laboratory data.

3 eries analysis was performed on microbiology laboratory data.

4 ge and is complicated by a lack of field and laboratory data.

5 lent diagnoses of lung cancer, or incomplete laboratory data.

6 ed the acquisition of extensive clinical and laboratory data.

7 ing demographic, clinical, instrumental, and laboratory data.

8 mographic, clinical, neurophysiological, and laboratory data.

9 mographic, clinical, neurophysiological, and laboratory data.

10 ts that are readily obtainable from clinical laboratory data.

11 ion efficiency was found from both field and laboratory data.

12 re based primarily on extensive experimental laboratory data.

13 wed that the results are consistent with the laboratory data.

14 f RNA-Seq was compared to available clinical laboratory data.

15 ved loose bowels and skin lesions as well as laboratory data.

16 hospitalization, treatment tolerability, and laboratory data.

17 ic findings in combination with clinical and laboratory data.

18 and ophthalmologists collected clinical and laboratory data.

19 rtant data that significantly complement the laboratory data.

20 -care testing (POCT) is rapid acquisition of laboratory data.

21 determined the cause of death and collected laboratory data.

22 endotherm that accurately predicts field and laboratory data.

23 l-of-care requirements based on clinical and laboratory data.

24 at least 2 orders of magnitude over previous laboratory data.

25 xplained by adverse events, microbiology, or laboratory data.

26 th baseline BNP levels and angiographic core laboratory data.

27 stribution of parameters consistent with the laboratory data.

28 can be attained from inverting the tailored laboratory data.

29 in/1.73 m(2) base on both out- and inpatient laboratory data.

30 Unmeasured confounding, incomplete laboratory data.

31 e model was constrained against clinical and laboratory data.

32 ing, insufficient, or early or late baseline laboratory data.

33 Clinical and laboratory data.

34 stantial structural problems and issues with laboratory data.

35 ly 78% of available electronic health record laboratory data.

36 measured NT-proBNP data (c-indices: 0.80 [w/laboratory data]-0.81 [full model]); net reclassificatio

37 identified comorbidities using pretransplant laboratory data, (2) investigate additional HCT-related

38 s-sectional analysis of survey and automated laboratory data 2969 primary care diabetic patients of a

39 S administrative claims database with linked laboratory data, 34 569 new users of oral anticoagulants

40 The laboratory data accurately reproduced real-world THM for

41 440 girls with both reproductive health and laboratory data, after accounting for BMI and race/ethni

42 Laboratory data allowed investigators to rapidly link in

43 If fatty liver was identified, then laboratory data and a liver biopsy were obtained.

44 Sepsis-related Organ Failure Assessment, and laboratory data and biomarkers of organ injury.

45 ified AKI events not requiring dialysis from laboratory data and classified them according to the rat

46 Previous and current therapy, laboratory data and clinical activity were recorded at t

47 However, there are now considerable laboratory data and clinical experience demonstrating sa

48 the type of colitis is based on clinical and laboratory data and colonoscopic and biopsy findings, bu

49 tation must be tested using a combination of laboratory data and evidence about cooperation "in the w

50 sing on the utility of physical examination, laboratory data and imaging (both ultrasonography and co

51 gregate sufficient longitudinal clinical and laboratory data and integrate these data with model syst

52 association between patient demographics or laboratory data and IOPTH half-life.

53 Laboratory data and radiographic response were measured

54 ing findings were compared with clinical and laboratory data and radiographic results.

55 -positive lesion plus consistent clinical or laboratory data and recommended confirmation by biopsy o

56 o received study drug by monitoring clinical laboratory data and self-report and direct clinician ass

57 The clinical and laboratory data and the findings of the initial US and M

58 confounding, missing data (namely incomplete laboratory data), and low baseline risk for gout.

59 orbid disease, physiology at admission (from laboratory data), and transfer status.

60 Demographics, comorbidities, vital signs, laboratory data, and ACEi/ARB usage were analyzed.

61 Demographic information, laboratory data, and diagnoses were extracted from the c

62 n, quality of life, adverse events, clinical laboratory data, and electrocardiogram results were asse

63 for patient diagnoses within the past year, laboratory data, and for clustering of patients within h

64 Demographic, clinical, and laboratory data, and HRCT imaging were collected and com

65 nt's clinical history, physical examination, laboratory data, and imaging.

66 Demographic information, laboratory data, and medication exposure were extracted

67 rs for acute kidney disease, physiologic and laboratory data, and outcomes were recorded.

68 ional electronic tuberculosis register data, laboratory data, and published studies.

69 CDI is a clinical diagnosis supported by laboratory data, and the detection of toxigenic C. diffi

70 ata, physical examination findings, or basic laboratory data; and (3) confirmed or excluded appendici

71 Screening laboratory data appears to be less sensitive to detect t

72 We parameterised the model with laboratory data, applied it to predict survival in the f

73 The laboratory data are acquired in ~ 12 min and the reconst

74 Limited clinical and laboratory data are available on patients with Ebola vir

75 if all the test-negative cases with missing laboratory data are EV71-HFMD.

76 Epidemiological and laboratory data are scarce among Andean and Mexico, Cent

77 inical, dual-energy X-ray absorptiometry and laboratory data, are also reported.

78 i-centre trans-sectional study, clinical and laboratory data as well as CSF and/or blood serum sample

79 Demographic and laboratory data as well as ICAD risk factors, including

80 Demographic, anthropometrical, and laboratory data, as well as family history of type 2 DM

81 Demographic, anthropometrical, and laboratory data, as well as immunosuppressive and antihy

82 th study groups were matched in clinical and laboratory data, as well as volume of injected contrast.

83 demographic factors, behavioral factors, and laboratory data associated with the metabolic syndrome.

84 ria for Adverse Events (version 3.0) for all laboratory data at regular follow-up visits and during o

85 ion was often related to missing clinical or laboratory data at the MDPH as well as restrictive defin

86 Taking hematologic laboratory data at ~3-month intervals (or as available)

87 pretransplant information including routine laboratory data available before or at the time of trans

88 rentiated febrile illness, with clinical and laboratory data available for 252 illness episodes.

89 ing the implementation of local and national laboratory data-based surveillance systems for the routi

90 Clinical and laboratory data before and 24 hours (h) after ICA were a

91 oncology combining anatomical, metabolic and laboratory data can be designed.

92 Laboratory data can be of some help, but not for all ant

93 This study investigates if laboratory data can be used to assess whether physician-

94 More generally we illustrate how clinical laboratory data can be used to develop and to test a dyn

95 no-scrotal sonography, supported by relevant laboratory data can clinch the accurate diagnosis.

96 of ADM with POA codes and readily available laboratory data can efficiently support accurate risk-st

97 ing present on admission codes and numerical laboratory data collected at the time of admission resul

98 afety was assessed through adverse event and laboratory data collection.

99 that a simple model using readily available laboratory data could be developed to predict imminent A

100 Rapidly ascertainable clinical and laboratory data could identify individuals at high risk

101 tive clinical data (clinical manifestations, laboratory data, disease activity, damage, and mortality

102 om clinical examinations, medical histories, laboratory data, drug use, and register linkages over 9

103 elected for tracing and missing clinical and laboratory data due to the use of medical records.

104 Direct observation of verbalized laboratory data during daily ICU rounds compared with da

105 Epidemiologic and laboratory data each generated large and dense networks.

106 Methods: Laboratory data, echocardiography, 6-min-walk testing, V

107 In addition to clinical and laboratory data, electrocardiograms (EKGs), chest radiog

108 Unfortunately, there are no basic laboratory data examining 8-OHdG levels in animal models

109 Clinical and laboratory data, food records, and activity logs were co

110 We retrospectively reviewed radiographic and laboratory data for all patients from a single center wh

111 ords for pertinent clinical, radiologic, and laboratory data for cryptococcal disease.

112 ysical examination, serum, or synovial fluid laboratory data for diagnosing septic arthritis.

113 However, the lack of laboratory data for Earth's most abundant mineral, (Mg,F

114 We used laboratory data for invasive pneumococcal disease (IPD)

115 We used laboratory data for invasive pneumococcal disease (IPD)

116 We analyzed demographic, clinical, and laboratory data for newly diagnosed pediatric (age <15 y

117 Epidemiologic, clinical, and laboratory data for outbreak cases residing in NYC were

118 The clinical and laboratory data for patients with positive cultures were

119 TB surveillance and laboratory data for specimens submitted 1 August 2012 th

120 We compiled clinical and laboratory data from 11 patients with hematological mali

121 Anonymized samples and laboratory data from 1491 African-American and 31 005 wh

122 tion models using demographic, clinical, and laboratory data from 2 independent Canadian cohorts of p

123 Using Truven Health MarketScan laboratory data from 2010-2015 we identified individuals

124 Clinical and laboratory data from 4,445 patients with NDMM enrolled o

125 database, which contains administrative and laboratory data from 6 pediatric hospitals in the United

126 tal CMV infection, we extracted clinical and laboratory data from 7 days before until 7 days after in

127 Laboratory data from 7,900 CT positive samples were incl

128 sign, we examined clinical, histological and laboratory data from 749 consecutive unselected CD child

129 Clinical and laboratory data from 80 untreated children with juvenile

130 Here, we used laboratory data from a rabbit-helminth system and develo

131 011, we prospectively collected clinical and laboratory data from all patients with Buruli ulcer diag

132 We analyzed clinical and laboratory data from blood culture-confirmed enteric fev

133 We extracted epidemiological, clinical, and laboratory data from cases of hand, foot, and mouth dise

134 Clinical and laboratory data from coeliac patients who later develope

135 We use both laboratory data from cytometry experiments as well as da

136 Clinical and laboratory data from each patient's hospital records wer

137 cted BMR, body-composition, demographic, and laboratory data from electronic databases of 757 volunte

138 We abstracted clinical and laboratory data from electronic medical records.

139 This study includes national laboratory data from invasive pneumococcal disease (IPD)

140 In a retrospective analysis of laboratory data from Oxford University Hospitals Nationa

141 assessment focused on detailed clinical and laboratory data from patients with suspected DILI.

142 a single laboratory validation data or inter-laboratory data from Proficiency Testing schemes.

143 By use of routinely collected laboratory data from South Africa's National HIV Program

144 Purpura (UK TTP) Registry with clinical and laboratory data from the largest cohort of pregnancy-ass

145 We combined laboratory data from the National Health and Nutrition E

146 ned retrospective demographic, clinical, and laboratory data from the period 2003-2007 for children h

147 ly assigned from ranges defined by field and laboratory data, generated an emergent community structu

148 Recent laboratory data have clarified a number of key mechanist

149 ith multidimensional phenotypes that include laboratory data, images, vital signs, and other clinical

150 All notes, laboratory data, imaging results, other diagnostic studi

151 rt study of Medicare beneficiaries linked to laboratory data in 10 states with prevalent heart failur

152 ico predictions were validated by subsequent laboratory data in NOD mice with T1D that received anti-

153 was performed for all available clinical and laboratory data in patients with biopsy-confirmed NSF.

154 inty in the risk of EV71-HFMD due to missing laboratory data in the national database, (ii) excluding

155 Clinical and laboratory data including serial Expanded Disability Sta

156 We collected various laboratory data including serum creatinine, calcium, pho

157 Laboratory data including serum fasting glucose, haemogl

158 Laboratory data including total and specific IgE were ev

159 gate the ability of patient characteristics, laboratory data (including MELD scores), and hemodynamic

160 Clinical and laboratory data, including 62.3+/-26.1 months follow-up

161 They demonstrated characteristic laboratory data, including increased lactate and/or pyru

162 Demographic, clinical, and laboratory data, including measures of 11 antibodies, we

163 emained stable over the study period, and no laboratory data indicated liver or kidney injury or dysf

164 Computer spreadsheet modeling results and laboratory data involving 16 pairs of analyte and intern

165 substituting clinical surrogates for missing laboratory data is an appropriate alternative to the con

166 model), POA-ADM supplemented with admission laboratory data (Laboratory model), Laboratory model sup

167 Pred to an additional seven isolates with no laboratory data led to types that clustered with identic

168 aphics, location of evaluation, clinical and laboratory data, major organ system dysfunction, 48-hr p

169 Vital signs at admission and laboratory data may be useful for risk stratification to

170 Demographic information, laboratory data, medical comorbidities, insurance and ad

171 PheWAS of EMR data, with linkage to laboratory data obtained from blood samples, provide a n

172 Consequently, laboratory data obtained on olivine separates might yiel

173 The clinical and laboratory data of 100 consecutive patients with repaire

174 The clinical and laboratory data of CA patients in a large electronic hea

175 pecies level in clinical samples may provide laboratory data of crucial importance in epidemiologic i

176 d between corneal morphological features and laboratory data of diabetic patients, ECD showed a signi

177 eatures with the general characteristics and laboratory data of diabetic patients, including disease

178 infection were reviewed retrospectively for laboratory data of hepatic parenchymal inflammation and

179 This was a review of clinical and laboratory data of men and women presenting to the Jeffe

180 ospective cohort study, we used clinical and laboratory data of patients who had haemopoietic cell tr

181 The association between laboratory data of patients with decreased DLCO or restr

182 The clinical presentation and laboratory data of the index patient were typical of mea

183 A retrospective chart review of clinical and laboratory data on 39 patients with CVID and GLILD who c

184 Laboratory data on 4,735 Neisseria meningitidis strains

185 r (DLC) exposures, we extrapolated published laboratory data on common terns to roseate terns by char

186 tract clinical, hemodynamic, medication, and laboratory data on patients admitted to the LTICU from M

187 del predictions are tested against available laboratory data on petroleum liquid densities, gas/liqui

188 by at least 30%, plus consistent clinical or laboratory data or confirmation by biopsy or correlative

189 xcluded because of a lack of clinical and/or laboratory data, pancreatic abnormalities, or inadequate

190 Results Demographics, laboratory data, performance, tumor characteristics, and

191 tus for each veteran was identified from HBV laboratory data performed prior to DAA initiation.

192 ical variables, such as presenting symptoms, laboratory data, peripheral oxygen saturation, and comor

193 cidin-25 level, and relevant demographic and laboratory data pertinent to posttransplantation anemia,

194 Missing clinical and laboratory data precluded evaluation of some reports.

195 oring system based on objective clinical and laboratory data provides meaningful risk stratification

196 NNDSS HCV case reports and Quest laboratory data regarding unique reproductive-aged women

197 t sign on physical examination and screening laboratory data remains controversial, although screenin

198 performed for a subset of patients with all laboratory data required to analyze the data via physica

199 ablished electronic health record, clinician laboratory data retrieval and communication during ICU r

200 In addition, recent laboratory data reveal glutamine may act via mechanisms

201 Laboratory data revealed proteinuria and severe depletio

202 Among subjects with available laboratory data, scores on the Framingham Cardiovascular

203 outside predefined CLSI criteria, the entire laboratory data set was excluded.

204 criteria resulted in exclusion of the entire laboratory data set.

205 Laboratory data show that acid-sulphate alteration, comm

206 ches were the most accurate when compared to laboratory data, showing great potential for predicting

207 Clinical laboratory data shows that most results are within the r

208 Among clinical and laboratory data studied, prevalences of leukocytosis, pr

209 Clinical and laboratory data sufficient to calculate Mortality in Eme

210 Epidemiologic, clinical, and laboratory data suggest that H5N1 influenza viruses are

211 Laboratory data suggest that harmful epinephrine-induced

212 Laboratory data suggest that intake of vitamin A and car

213 Laboratory data suggest that the role of dopamine in mig

214 Laboratory data suggested that bicarbonate enhanced the

215 ntaneous macromolecular damage inferred from laboratory data, suggesting that microbes imprisoned in

216 ting for patient demographics, case-mix, and laboratory data, suggesting the involvement of other fac

217 fish production, and all published field and laboratory data support the conclusion that something ot

218 Observational and recent laboratory data support the need for randomized clinical

219 thematical model developed and fitted to the laboratory data supported the hypothesis that EhV replic

220 transferase levels were the only clinical or laboratory data that independently predicted severity of

221 This study provides laboratory data that may be used by doctors to advise po

222 These conclusions are supported by laboratory data that subsequently identified three addit

223 Without artificial tuning to the laboratory data, the model showed excellent predictive a

224 intensive care unit patient stays, including laboratory data, therapeutic intervention profiles such

225 ing present on admission codes and numerical laboratory data to administrative claims data.

226 n study limitation was the unavailability of laboratory data to assess specific types or severity of

227 and accuracy of clinical, radiographic, and laboratory data to diagnose bacterial VAP relative to a

228 memory B cells, while gathering longitudinal laboratory data to examine the progressive nature of the

229 118), we collected clinical and longitudinal laboratory data to investigate relationships between sTN

230 measured and readily available clinical and laboratory data to separate NAFLD patients with and with

231 We discuss the potential for scaling these laboratory data to three-dimensional canopy space.

232 ew approaches to analyzing epidemiologic and laboratory data to understand transmission during this o

233 eclassification index improved from 0.035 (w/laboratory data) to 0.085 (complete model).

234 inside village kitchens, in conjunction with laboratory data, to assess the health impacts of new coo

235 importance of considering epidemiologic and laboratory data together when evaluating potential etiol

236 regimens, ammonia levels and other pertinent laboratory data, treatments administered, and outcomes w

237 tology, physical exam data, imaging studies, laboratory data, vaping history, and subsequent outpatie

238 ure compares model predicted values with the laboratory data via the standard Bayesian techniques wit

239 Laboratory data, vital signs, slit lamp examination, bes

240 ed with admission vital signs and additional laboratory data (VS model), VS model supplemented with k

241 A multivariable model using routine laboratory data was able to predict advanced chronic kid

242 On the basis of a synthesis of clinical and laboratory data, we developed a biological functions cla

243 Addressing clinical and laboratory data, we discuss emerging features for the ef

244 Using commercial laboratory data, we found 80% of 29382 young persons cur

245 ng Taylor's Power Law to integrate field and laboratory data, we found that only treatments involving

246 Using our laboratory data, we have developed a Markov change model

247 he endoscopic reports, clinical records, and laboratory data were also reviewed and compared with the

248 Clinical and laboratory data were also used to assess the value of HD

249 Clinical and laboratory data were analyzed for correlates of response

250 Demographic and laboratory data were analyzed in participants (n = 4814,

251 m within 24 hours of the visit, and abnormal laboratory data were available for review within a media

252 There was unmeasured confounding and no laboratory data were available for the majority of patie

253 neumonia.Methods: Clinical, physiologic, and laboratory data were collated.

254 Physiologic data collection occurred hourly; laboratory data were collected according to local ICU pr

255 Demographic, clinical, and laboratory data were collected and blood samples for ROT

256 Laboratory data were collected at baseline and 1 mo afte

257 Demographic, physiologic, and laboratory data were collected before initiation, 2 hrs

258 Clinical and laboratory data were collected for 323 adults with radio

259 Demographic, physiological, and laboratory data were collected for as long as NPPV was p

260 h case-based surveillance, epidemiologic and laboratory data were collected for each case.

261 Clinical and laboratory data were collected from each subject.

262 Demographic, hemodynamic, and laboratory data were collected in all ICU patients who w

263 in MRI, cardiac MRI, neuropsychological, and laboratory data were collected on 1504 Framingham Offspr

264 Retrospective clinical and laboratory data were collected on 89 patients of pulmona

265 utcomes and Measures: Extensive clinical and laboratory data were collected on patients who were subc

266 Detailed epidemiologic and laboratory data were collected on suspected meningitis c

267 Clinical and laboratory data were collected retrospectively.

268 Epidemiological, clinical, and laboratory data were collected using a standardized case

269 Upon admission, clinical and laboratory data were collected, King's College Criteria

270 Survey, anthropometric measurements, and laboratory data were collected.

271 Demographic, clinical, and laboratory data were collected.

272 Clinical and laboratory data were collected.

273 Clinical, histologic, and laboratory data were compared using nonparametric statis

274 Their epidemiological, clinical, and laboratory data were extracted and stratified by month,

275 Vital sign, demographic, location, and laboratory data were extracted from the electronic healt

276 Participant characteristics and laboratory data were extracted.

277 Clinical and laboratory data were gathered on 10,750 previously untre

278 After 1 year, her symptoms and her laboratory data were improved.

279 n, 6.3 per patient) and 38.9% of all audited laboratory data were inaccurately communicated.

280 Clinical and laboratory data were linked for all patients presenting

281 Individual clinical, pharmacy, and laboratory data were merged using individual hospital id

282 Clinical and laboratory data were obtained from 696 patients with CID

283 Socio-demographic, clinical, and laboratory data were obtained from all suspected or conf

284 ultrasound examination was performed and the laboratory data were obtained.

285 Clinical and laboratory data were obtained.

286 erioperative, and postoperative clinical and laboratory data were prospectively collected and compare

287 Clinical and laboratory data were recorded for every patient.

288 Basic demographic and laboratory data were recorded.

289 Physiologic and laboratory data were recorded.

290 wo-plane radiographs, clinical findings, and laboratory data were reviewed in 13 children (median age

291 Clinical and laboratory data were reviewed.

292 nd sleep apnea, and changes in corresponding laboratory data were studied.

293 The rest of the laboratory data were unremarkable.

294 ities, hospital procedures, medications, and laboratory data were used to develop a model to predict

295 Additional laboratory data were used to track cases.

296 including the corresponding radiographs and laboratory data, were prospectively reviewed by one of t

297 Correlations of clinical and laboratory data with urinary and serum levels of lipocal

298 e extensively investigated with clinical and laboratory data, with a follow-up of at least 18 months.

299 rct location, coronary anatomy, and clinical laboratory data, with final follow-up through December 3

300 ing etiologies based on initial clinical and laboratory data would facilitate etiology-based treatmen